Human RCTPubMed ID: 37351564·2023

Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes

Rosenstock J, et al.

New England Journal of Medicine, 2023 · n = 338

Key finding

Retatrutide 12mg produced mean weight loss of 24.2% at 48 weeks, the highest reported for any anti-obesity medication in trials.

Summary

Phase 2 trial showing retatrutide produced up to 24.2% body weight loss at 48 weeks, surpassing tirzepatide results.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

RetatrutideL4

A triple-acting GIP/GLP-1/glucagon receptor agonist in Phase 3 trials showing potentially the highest weight loss of any drug in development.

More research on Retatrutide

TRIUMPH-NAS: Retatrutide for Non-Alcoholic Steatohepatitis

Journal of Hepatology · 2025 · Human RCT

TRIUMPH-OA: Retatrutide for Obesity-Related Osteoarthritis

Osteoarthritis and Cartilage · 2025 · Human RCT

Genetic Polymorphisms Predict Retatrutide Response: GWAS Analysis

Cell Metabolism · 2025 · Human RCT

Comparative Efficacy: Retatrutide vs Tirzepatide in Randomized Head-to-Head Trial

New England Journal of Medicine · 2025 · Human RCT

TRIUMPH 1: Retatrutide versus Placebo in Obesity (Phase 3)

Lancet Diabetes & Endocrinology · 2024 · Human RCT